Peptides by condition · Hormones and sexual health
Peptides studied for polycystic ovary syndrome (PCOS)
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 4 study pages on polycystic ovary syndrome (PCOS): 4 in people (3 of them meta-analyses or randomized trials). They studied 2 compounds, with this many study pages each: Clomiphene 2 and Exenatide 2.
What the research on polycystic ovary syndrome (PCOS) looks like
Polycystic ovary syndrome (PCOS) is a common hormone condition in women: periods come rarely or not at all, the ovaries release eggs irregularly, and male-type hormones run high. It often comes with insulin resistance and extra weight, and it is a common reason women have trouble getting pregnant. The studies here tested an older fertility pill, clomiphene, which prompts the ovary to release an egg, and a GLP-1 drug, exenatide, given for weight and blood sugar.
Fertility studies count how many women ovulated, became pregnant and gave birth. Metabolic studies measure weight, blood sugar and insulin, and the hormones the ovaries make, such as testosterone.
Check what a drug was compared with: another fertility drug, metformin or nothing. A pregnancy rate depends on how long women were followed and on what else they took, and these studies were mostly in one country, so the women studied may differ from others with PCOS.

The 4 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Clomiphene
2 in peopleFor polycystic ovary syndrome (PCOS), 2 of our study pages are filed under Clomiphene: 1 meta-analysis and 1 observational study in people. The largest in people pooled 1,270 people and was published in 2024. They were published from 2024 to 2026, in BMC Womens Health and Front Endocrinol (Lausanne).
FDA-approved, with a use tied to polycystic ovary syndrome (PCOS) on its label: Clomid (tablet) for ovulation problems in women who want to become pregnant.
- Meta-analysis in people · 1,270 people · 2024Clomiphene plus dexamethasone raised pregnancy rates in PCOS
- Observational study in people · 471 people · 2026Clomiphene: 6.8% of women with PCOS were resistant in PCOSAct
Exenatide
2 in peopleFor polycystic ovary syndrome (PCOS), 2 of our study pages are filed under Exenatide: 2 randomized trials in people. The largest in people enrolled 160 people and was published in 2022. They were published from 2021 to 2022, in Arch Gynecol Obstet and J Clin Endocrinol Metab.
FDA-approved for other uses, not for polycystic ovary syndrome (PCOS): Byetta (injection) for blood sugar control, with diet and exercise, in adults with type 2 diabetes.
- Randomized trial in people · 160 people · 2022Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOS
- Randomized trial in people · 119 people · 2021Exenatide, alone or with dapagliflozin, improved blood sugar in PCOS
Side by side
For the 2 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Clomiphene | 2 | 0 | 1,270 | Approved, a use tied to it |
| Exenatide | 2 | 0 | 160 | Approved for other uses |
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 1,270
- FDA
- Approved, a use tied to it
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 160
- FDA
- Approved for other uses
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Clomiphene plus dexamethasone raised pregnancy rates in PCOSIt pools 12 earlier studies, so its results are only as solid as those studies. It covers only women with PCOS, and side effects were checked as adverse reactions, dizziness and vomiting.
- Clomiphene: 6.8% of women with PCOS were resistant in PCOSActThis was a post hoc look at one arm of a trial, so it shows links, not cause and effect, and it was based on only 32 women who were resistant. All the women were in China and had to have completed follow-up, so the results may not apply to everyone with PCOS.
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSExenatide was given for only 12 weeks, and the study included only Chinese women with PCOS and excess weight. The links with weight loss and insulin resistance come from a statistical model, not a direct test of cause.
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSThe trial ran 24 weeks and had no placebo arm, so every group got an active drug. It included only women without diabetes who had obesity and PCOS, so it doesn't show how these drugs work in other groups.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for polycystic ovary syndrome (PCOS)?
Our 4 study pages on polycystic ovary syndrome (PCOS) are filed under 2 compounds, with this many each: Clomiphene 2 and Exenatide 2. Clomiphene and Exenatide have the most, 2 each.
Have any been tested in people with polycystic ovary syndrome (PCOS)?
Yes: all 4 were in people, 3 of them meta-analyses or randomized trials (Clomiphene and Exenatide). The largest pooled 1,270 people: “Clomiphene plus dexamethasone raised pregnancy rates in PCOS” (2024).
Is any peptide FDA-approved for polycystic ovary syndrome (PCOS)?
Yes, with a use tied to polycystic ovary syndrome (PCOS) on their FDA labels: Clomiphene as Clomid. 1 other compound here with an FDA record has no use tied to it.
How large were the studies in people on polycystic ovary syndrome (PCOS)?
Of the 4 in people, all give their size on our pages: 1 had 1,000 people or more and 3 had 100 to 999. The largest, a meta-analysis from 2024, pooled 1,270.
What is the newest study on polycystic ovary syndrome (PCOS) here?
Of our study pages on polycystic ovary syndrome (PCOS), the newest is “Clomiphene: 6.8% of women with PCOS were resistant in PCOSAct”, an observational study in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.